AU2009289809B2 - Screening methods for transfusion related acute lung injury (TRALI) - Google Patents

Screening methods for transfusion related acute lung injury (TRALI) Download PDF

Info

Publication number
AU2009289809B2
AU2009289809B2 AU2009289809A AU2009289809A AU2009289809B2 AU 2009289809 B2 AU2009289809 B2 AU 2009289809B2 AU 2009289809 A AU2009289809 A AU 2009289809A AU 2009289809 A AU2009289809 A AU 2009289809A AU 2009289809 B2 AU2009289809 B2 AU 2009289809B2
Authority
AU
Australia
Prior art keywords
hna
seq
fragment
sample
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009289809A
Other languages
English (en)
Other versions
AU2009289809A8 (en
AU2009289809A1 (en
Inventor
Jurgen Bux
Andreas Greinacher
Angelika Reil
Jan Wesche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Greifswald
DRK Blutspendedienst West gGmbH
Original Assignee
Ernst Moritz Arndt Universitaet Greifswald
DRK Blutspendedienst West gGmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ernst Moritz Arndt Universitaet Greifswald, DRK Blutspendedienst West gGmbH filed Critical Ernst Moritz Arndt Universitaet Greifswald
Publication of AU2009289809A1 publication Critical patent/AU2009289809A1/en
Publication of AU2009289809A8 publication Critical patent/AU2009289809A8/en
Priority to AU2016204135A priority Critical patent/AU2016204135A1/en
Application granted granted Critical
Publication of AU2009289809B2 publication Critical patent/AU2009289809B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009289809A 2008-09-04 2009-09-03 Screening methods for transfusion related acute lung injury (TRALI) Active AU2009289809B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016204135A AU2016204135A1 (en) 2008-09-04 2016-06-17 Screening methods for transfusion related acute lung injury (TRALI)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008045696.9 2008-09-04
DE102008045696A DE102008045696A1 (de) 2008-09-04 2008-09-04 Granulozyten HNA-3a/b-Antigen
PCT/EP2009/006386 WO2010025915A1 (en) 2008-09-04 2009-09-03 Screening methods for transfusion related acute lung injury (trali)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016204135A Division AU2016204135A1 (en) 2008-09-04 2016-06-17 Screening methods for transfusion related acute lung injury (TRALI)

Publications (3)

Publication Number Publication Date
AU2009289809A1 AU2009289809A1 (en) 2010-03-11
AU2009289809A8 AU2009289809A8 (en) 2011-05-12
AU2009289809B2 true AU2009289809B2 (en) 2016-07-07

Family

ID=41266687

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2009289809A Active AU2009289809B2 (en) 2008-09-04 2009-09-03 Screening methods for transfusion related acute lung injury (TRALI)
AU2016204135A Abandoned AU2016204135A1 (en) 2008-09-04 2016-06-17 Screening methods for transfusion related acute lung injury (TRALI)

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016204135A Abandoned AU2016204135A1 (en) 2008-09-04 2016-06-17 Screening methods for transfusion related acute lung injury (TRALI)

Country Status (9)

Country Link
US (4) US8084216B2 (https=)
EP (1) EP2321644B1 (https=)
JP (1) JP5766606B2 (https=)
CN (1) CN102203609B (https=)
AU (2) AU2009289809B2 (https=)
BR (1) BRPI0918233B8 (https=)
CA (1) CA2735138C (https=)
DE (1) DE102008045696A1 (https=)
WO (1) WO2010025915A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2162792A4 (en) 2007-05-29 2011-08-24 Lab Partners Associates Inc SYSTEM AND METHOD FOR MAINTAINING FLASH CONTACT COMMUNICATIONS BETWEEN A CAMERA AND A WIRELESS DEVICE
WO2009114522A2 (en) * 2008-03-10 2009-09-17 Bonfils Blood Center Compositions, kits and methods for determining etiology of trali and detecting patients at risk for this transfusion reaction
DE102008045696A1 (de) * 2008-09-04 2010-03-11 Drk Blutspendedienst West Ggmbh Granulozyten HNA-3a/b-Antigen
WO2010059971A1 (en) * 2008-11-21 2010-05-27 Martin Heath Bluth Diagnosing and monitoring response to treatment of non-incontinent urological and related diseases
WO2010065425A1 (en) 2008-12-01 2010-06-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
US10101337B2 (en) 2013-03-14 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting donor-specific antibodies and systems for practicing the same
EP3140322B1 (en) * 2014-05-09 2021-02-17 One Lambda, Inc. Modified fc gamma receptor type iii (fc iii, hna-1) polypeptides and the uses thereof
US10527613B2 (en) 2015-11-10 2020-01-07 The Board Of Trustees Of The Leland Stanford Junior University Biomarker detection methods and systems and kits for practicing same
WO2017094733A1 (ja) * 2015-11-30 2017-06-08 日産化学工業株式会社 分子標的医薬に結合するｄｎａアプタマー及びそれを用いる分子標的医薬の検出方法
AU2016402264B2 (en) * 2016-04-15 2024-08-22 Pontificia Universidad Católica De Chile Pharmaceutical composition for reducing the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralises the function of the TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and the use thereof
CN116083551B (zh) * 2022-10-11 2025-02-21 南宁中心血站(南宁输血医学研究所) 用于检测人类中性粒细胞抗原基因分型的引物组合、试剂盒及方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219777A1 (en) * 2001-12-18 2003-11-27 Lynx Therapeutics, Inc. Identification of candidate genes for the atherosclerosis susceptibility locus (ATHS)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US20030082646A1 (en) 1998-12-29 2003-05-01 The Regents Of The University Of Michigan Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL
CA2383592A1 (en) 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
FR2800750B1 (fr) 1999-11-05 2003-01-31 Centre Nat Rech Scient Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
DE10028725B4 (de) 2000-06-09 2013-03-21 Jürgen Bux Primärstruktur des HNA-2a (ehemals NB1)-Antigens
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US7829292B2 (en) 2002-05-06 2010-11-09 The Regents Of The University Of Michigan Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
CA2516128A1 (en) * 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic targets in cancer
US7303985B2 (en) 2003-11-17 2007-12-04 Intel Corporation Zeolite-carbon doped oxide composite low k dielectric
WO2007108368A1 (ja) * 2006-03-23 2007-09-27 Japanese Red Cross Society 顆粒球抗体の検出に用いられるパネル細胞
DE102008045696A1 (de) * 2008-09-04 2010-03-11 Drk Blutspendedienst West Ggmbh Granulozyten HNA-3a/b-Antigen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219777A1 (en) * 2001-12-18 2003-11-27 Lynx Therapeutics, Inc. Identification of candidate genes for the atherosclerosis susceptibility locus (ATHS)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVOREN, A. et al., Transfusion, 2003, Vol. 43, No. 5, pages 641-645 *

Also Published As

Publication number Publication date
US20150203915A1 (en) 2015-07-23
EP2321644B1 (en) 2016-12-14
JP2012501631A (ja) 2012-01-26
BRPI0918233B1 (pt) 2020-12-01
US20120070834A1 (en) 2012-03-22
CN102203609B (zh) 2017-07-11
US8084216B2 (en) 2011-12-27
US20100055706A1 (en) 2010-03-04
BRPI0918233A2 (pt) 2015-12-15
CA2735138A1 (en) 2010-03-11
CN102203609A (zh) 2011-09-28
WO2010025915A1 (en) 2010-03-11
AU2009289809A8 (en) 2011-05-12
US20130189696A1 (en) 2013-07-25
US8999651B2 (en) 2015-04-07
US8435733B2 (en) 2013-05-07
EP2321644A1 (en) 2011-05-18
BRPI0918233B8 (pt) 2021-07-27
CA2735138C (en) 2021-06-01
US9963741B2 (en) 2018-05-08
AU2009289809A1 (en) 2010-03-11
AU2016204135A1 (en) 2016-07-14
JP5766606B2 (ja) 2015-08-19
DE102008045696A1 (de) 2010-03-11

Similar Documents

Publication Publication Date Title
AU2009289809B2 (en) Screening methods for transfusion related acute lung injury (TRALI)
JP4969638B2 (ja) 単球由来核酸および関連する組成物ならびに方法
CA2814029C (en) Moesin fragments associated with immune thrombocytopenia
CA2814026C (en) Moesin fragments associated with aplastic anemia
US9079961B2 (en) GPIIIa gene
WO2022007283A1 (zh) 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质
US10761098B2 (en) Methods and tools for Vel blood group typing
JP2010187556A (ja) 妊孕性診断方法、妊孕性診断キット、ポリヌクレオチド、ポリペプチド、及び抗体
CN101001879A (zh) 与胎儿而非成体cd34+/cd36+细胞结合的抗体
US20230257450A1 (en) antiRPS4Y1 mAb
US7160697B2 (en) Use of novel cytokine receptors as biomarkers and therapeutic targets in human cancer
WO2023156586A1 (en) Antirps4y1 mab
CA2885967C (en) Methods and tools for vel blood group typing
Cox The relevance and impact of MICA allele mismatching and MICA antibodies on renal transplantation outcome
JP2010158188A (ja) 妊孕性診断方法、妊孕性診断キット、ポリヌクレオチド、ポリペプチド、及び抗体
EP3140322A2 (en) Modified fc gamma receptor type iii (fc iii, hna-1) polypeptides and the uses thereof

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 25, NO 11, PAGE(S) 1297 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ERNST-MORITZ-ARNDT UNIVERSITAT GREIFSWALD; DRK BLUTSPENDEDIENST WESY GMBH, APPLICATION NUMBER 2009289809, UNDER INID (71) CORRECT THE APPLICANT NAME TO DRK BLUTSPENDEDIENST WEST GMBH

FGA Letters patent sealed or granted (standard patent)